In this engaging discussion, Harry Erba, a professor at Duke University, shares insights on prolonging remission in acute myeloid leukemia (AML). Joined by Farhad Ravandi from MD Anderson, they delve into the significance of measurable residual disease (MRD) assays in customizing post-remission therapies. Thomas Cluzeau from Central University Hospital of Nice emphasizes the role of allogeneic stem cell transplantation and innovative maintenance therapies. The trio explores new treatments like CPX351 and the essential nature of ongoing clinical trials to improve patient survival.